News | Events | Publications

Happy Holidays from our home offices to yours

December 15, 2020

With 2020 coming to a close, it is an opportune time to pause and reflect on the progress we have made as an industry, as a company and as individuals. We congratulate our partners and friends for their ingenuity and perseverance in rising to the challenges of the year.

View

“Stratification of patients based on the neuropathic pain symptom inventory (NPSI): development and validation of a new algorithm” published in Pain.

November 18, 2020

The journal article “Stratification of patients based on the neuropathic pain symptom inventory (NPSI): development and validation of a new algorithm”, has been published ahead of print in the journal Pain. This article was authored by Didier Bouhassira, MD, Director of Research at the National Institute for Health and Medical Research (INSERM) in France and member of Tools4Patient’s scientific advisory board, and was co-authored by Tools4Patient scientists Samuel Branders PhD, Alvaro Pereira PhD and Dominique Demolle, PhD.

View

There are currently no future events.
See our events archive for our previous event attendance.

From covariates to confounding factors: the danger of having too many covariates

October 20, 2020

Clinical trials typically evaluate efficacy of experimental therapies in heterogeneous patient populations, as patient characteristics

Read More

Regulatory Guidelines for the Use of Baseline Covariates to Increase Clinical Trial Study Power

October 15, 2020

Clinical trials data analyses can employ baseline covariates to control for factors that may impact

Read More

Does the placebo response need to be considered in clinical trials for COVID-19 vaccines and treatments?

September 22, 2020

The search for drugs to treat and prevent SARS-CoV-2 infection is ongoing, with more than 1200 drugs in the pipeline and more 3,200 clinical trials planned or initiated as of 21 September 2020 (GlobalData). The success of these studies, however, may be at risk due to an invisible threat – the placebo response.

Read More

Frequently asked questions about COV-IQ

September 16, 2020

This webinar aimed to explain the impact of COVID-19 crisis on patient behavior in ongoing clinical trials, introduce the application of COV-IQ technology and describe how it may improve interpretation of clinical trial results. During the webinar, questions from the audience were addressed; the main ones are compiled below.

Read More

Modelling of PNP and OA Placebo Response: Working towards a unique model of the placebo response in chronic pain?

In analgesia randomized clinical trials (RCTs), the magnitude and the variability of the placebo response negatively impacts the ability to demonstrate superiority of active compounds compared to placebo. The first objective of this analysis was to investigate parameters influencing the placebo response in PNP as a way to control for this major confounding factor.

Type: Scientific Poster

Authors: Samuel Branders, PhD ; Alvaro Pereira, PhD ; Erica Smith, PhD ; Dominique Demolle, PhD.

Date: February 2020

Conference: CNS Clinical Trials and Methodology (ISCTM)

Identification Of Peripheral Neuropathic Pain Sensory Phenotypes Based On Specific Combinations Of Symptoms Identified With The NPSI (Neuropathic Pain Symptom Inventory)

One way to better personalized the treatment of peripheral neuropathic pain (PNP) would be to identify specific sensory phenotypes of patients responding to different classes of drugs.

Type: Scientific Presentation

Authors: Didier Bouhassira(1), Samuel Banders(2), Nadine Attal(1), Dominique Demolle(2) and Alvaro Pereira(2). 1- Inserm 987, Ambroise Pare Hospital, 92100 Boulogne-Billancourt, France 2- Tools4Patient, 50 rue de Bordeaux, boîte 17, 6040 Jumet, Belgium

Date: September 2019

Conference: European Pain Federation (EFIC)

Leveraging Historical Data For High-dimensional Covariate-adaptive Randomization, A Machine Learning Approach.

There is a continuous growth in data collected in clinical trials. Many of those patient’s characteristics are potential confounding factors. Ideally, these factors should be accounted for in the randomization process to balance study arms and reduce the variability of the estimated treatment effect.

Type: Scientific Presentation

Authors: Samuel Branders, PhD; Guillaume Bernard, PhD; Alvaro Pereira, PhD

Date: June 2019

Conference: Promoting Statistical Insight Conference

Learn the importance of considering patient psychological traits, expectations, perception of patient relationship with the trial physician and staff, and social structure in efforts to understand the impact of the COVID-19 pandemic on clinical trials.

Date: June 2020

Erica Smith, VP of Business Development, speaks with Daniel Levin of The Bio Report Podcast about the Placebell©™ method to reduce the impact of the placeb response in drug development”.

Date: June 2019

Learn about how Tools4Patient considers the placebo response of each individual patient in clinical trials as a central part of the Placebell© methodology.

Date: March 2019

Erica Smith, VP of Business Development, discusses the benefits of the Placebell©™ approach in video interview at Biotech Showcase in San Francisco, CA.
Date: January, 2019

Date: January 2019

Sign up to join our regular newsletter.
Be the first to receive the latest innovations and news from Tools4Patient.